Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- Experts weigh in on liability over AI use in healthcare (Healio)
- Ascension’s Outpatient Surgery Volume Rose Nearly 400% After AMSURG Buy (ASC News)
- CMS Finalizes Reassignment of Gastric Alimetry® Test to Higher Payment Level, Increasing Medicare Hospital Outpatient Payment by Approximately 144% (Globe Newswire )
- MedInTech Secures $25.7 Million for AI Robotics Expansion (DistilINFO)
- AI-assisted colonoscopy and disease-specific imaging show benefits in ulcerative colitis (Hospital Healthcare Europe)
- The race to understand why young people are dying from colon cancer (Scientific American)
- What the Robot Still Can’t Do (NEJM)
- Geneoscopy Resolves Patent and False Advertising Litigation with Exact Sciences Following a Series of Victories at the Patent Trial and Appeal Board (PR Newswire)
